Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001507946 | SCV001713804 | likely pathogenic | not provided | 2019-09-05 | criteria provided, single submitter | clinical testing | PVS1, PM2 |
Neuberg Centre For Genomic Medicine, |
RCV003339656 | SCV004047180 | likely pathogenic | Elliptocytosis 1 | 2023-05-20 | criteria provided, single submitter | clinical testing | The observed frameshift c.1744dup(p.Thr582AsnfsTer5) variant in EPB41 gene has not been reported previously as a pathogenic variant nor a benign variant, to our knowledge. The p.Thr582AsnfsTer5 variant is absent in gnomAD Exomes. This variant has been reported to the ClinVar database as Likely Pathogenic. This variant causes a frameshift starting with codon Threonine 582, changes this amino acid to Asparagine residue, and creates a premature Stop codon at position 5 of the new reading frame, denoted p.Thr582AsnfsTer5. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants have been previously reported to be disease causing. For these reasons, this variant has been classified as Likely Pathogenic. |